Research into antibiotic-resistant priority pathogens has boomed in the five years since the World Health Organisation (WHO) released a list of 12 families of bacteria that desperately need new antibiotics.  Data from Elseveir’s Scopus database show that since 2017, 227,808 papers have been published on the 12 pathogens. The WHO released a list of bacteria […]

World Antimicrobial Awareness Week highlights the fact that antimicrobials have formed the bedrock of modern medicine, making surgeries, cancer care and treatments for life-threatening infections possible and improving human health in the process.  For years now, experts have laboured against the rise of antimicrobial resistance (AMR), urging governments to put in place policies that promote […]

Seven pharmaceutical companies have announced a joint initiative to reduce near-term emissions and help develop net zero health systems.   CEOs from AstraZeneca, GSK, Merck KGaA, Novo Nordisk, Roche, Samsung Biologics and Sanofi announced commitments to tackle climate change through the Sustainable Markets Initiative (SMI) Health Systems Task Force, a public-private partnership launched last year at […]

Michael Frisby, Partner at Stevens & Bolton LLP, examines where legal disputes are likely to occur within the pharmaceutical industry.  The current economic environment has fuelled fears of recession and with it a rise in disputes. But where are disputes likely to arise for life sciences businesses and what can be done?  Issues within the […]

GSK has announced strong quarterly results, reporting sales of £7.8 billion and growth in various sectors of the business.   Overall, the company’s adjusted operating profit for the third quarter came in at £2.6 billion, a 17% increase compared to the same period last year and reflecting a 4% year-on-growth at CER.   The quarterly results are […]

A research team from Boston University has caused controversy for work involving the creation of a hybrid SARS-CoV-2 virus.  Researchers from Boston University’s National Emerging Infectious Diseases Laboratories conducted a study1 to create a chimeric virus which combined the spike protein of the Omicron variant with the initial Wuhan strain of Covid-19.    The idea behind […]

By DDW Editor Reece Armstrong  The threat of antimicrobial resistance (AMR) has long been a talking point for those invested in healthcare and life sciences. Indeed, for many, it is a looming threat for which inaction could result in very serious consequences for healthcare systems worldwide.   AMR is currently listed as one of the top […]

Arndt Asperger, Senior Applications Scientist, Bruker Daltonics and Meike Hamester, Vice President Label-Free Technologies, Bruker Daltonics, examine how challenges in mass spectrometry for high-throughput screening can be overcome using a label-free approach.   Mass spectrometry is inherently appealing for high-throughput screening (HTS), because it avoids certain drawbacks of label-based assays, but long-standing limitations of cost per sample, […]

Professor Michael Butler, head of the National Institute for Bioprocessing Research and Training (NIBRT) Cell Technology Group (CTG), explains that the characterisation and analysis of glycans is important for the biopharma sector as it can help in the development of therapeutic agents such as monoclonal antibodies and other recombinant proteins. These are used in therapies […]

DDW sits down with Mark Matson, Senior Solution Specialist for Sensor Cloud at Medidata, a Dassault Systèmes company, about the use of digital biomarkers in life sciences and how they can help advance our understanding of disease.  How do we define digital biomarkers?  Digital biomarkers are data, or metrics, collected using digital health technologies to help describe […]